Signaling Pathway News and Research

RSS

Iowa State study identifies potential new target for leukemia treatment

In leukemia's most aggressive forms, the blood cell factories in our bone marrow falter. Instead of dividing and multiplying at their usual prolific pace, generating hundreds of billions of new cells daily, some precursor cells stall out at an immature stage.

24 Jul 2026

Genetic background shapes cancer development despite identical risk factors

Why do cancers develop differently in different people-even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism's genetic makeup significantly influences the course of cancer development.

22 Jul 2026

Dysregulation of immune regulator NF-κB drives major human diseases

NF‑κB controls genes involved in inflammation, immunity, cell survival, and proliferation. Triggered by cytokines (TNF‑α, IL‑1β), microbial products, or cellular stress, it translocates to the nucleus and induces pro‑inflammatory mediators.

13 Jul 2026

Stem cell study uncovers molecular pathway for enamel regeneration

Tooth enamel is the hardest substance in the human body, yet once damaged, it cannot regenerate naturally.

9 Jul 2026

Setmelanotide shows promise for hypothalamic obesity after brain tumors

A new therapy helps achieve a healthier BMI in people whose weight has become dysregulated following treatment for a brain tumor, a clinical trial has found.

8 Jul 2026

Bio-Techne launches expanded R&D Systems AI-Engineered Designer Protein Portfolio

Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows.

From Bio-Techne 8 Jul 2026

Blocking nerve signaling may reduce cancer-associated cachexia

Researchers have uncovered a previously unrecognized pathway linking lung tumor genetics, diet, and the nervous system that drives cancer-associated cachexia, according to a new study in mice.

2 Jul 2026

Evolutionary noncoding RNAs reveal new targets for cancer therapy

In cancer research, one person's junk is increasingly becoming another person's treasure. Scientists have now uncovered new evidence showing how recently evolved "junk DNA" genetic elements can become integrated into ancient cellular pathways that regulate cancer.

1 Jul 2026

Probiotic metabolite found to suppress melanoma tumor growth in mice

Immune checkpoint inhibitors like anti-PD-1 have transformed melanoma treatment, yet more than half of patients fail to respond or eventually develop resistance.

30 Jun 2026

Melatonin dampens fetal membrane inflammation linked to preterm birth

Melatonin reduced infection-related inflammation in human fetal membranes in an ex vivo model. The study suggests that this effect works partly through melatonin receptors and by suppressing the TLR4/MyD88/NF-κB pathway.

28 Jun 2026

Natural compound puerarin may protect against cholestatic liver fibrosis

A recent study published in Current Molecular Pharmacology demonstrates that puerarin-a bioactive isoflavone derived from Kudzu root and widely used in traditional Chinese medicine-may offer significant therapeutic benefits against cholestatic liver fibrosis, a progressive pathological condition arising from impaired bile formation and flow that currently lacks effective pharmacotherapies.

25 Jun 2026

Microbes trigger cell death to boost cancer immunotherapy effectiveness

Traditional cancer treatments like chemotherapy and radiotherapy can induce immunogenic cell death (ICD), but their efficacy is often limited by drug resistance, severe off-target toxicity, and immune-related adverse events.

24 Jun 2026

LMU researchers discover new genetic cause of Crohn's disease

A team led by LMU physician Daniel Kotlarz has identified a previously unknown genetic cause of Crohn's disease.

24 Jun 2026

Scientists uncover new molecular mechanism driving gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, with KIT mutations driving approximately 75% to 80% of cases.

23 Jun 2026

New protein discovery could lead to safer antithrombotic therapies

Antiplatelet drugs are one of the main tools used to prevent thrombus formation in people who have had a heart attack or stroke or who have cardiovascular diseases with a high thrombotic risk.

17 Jun 2026

Novel metal-free prodrug suppresses cancer spread in preclinical models

A carefully designed metal-free carbon monoxide prodrug may help prevent some of the deadliest forms of cancer from spreading, according to researchers at Weill Cornell Medicine.

12 Jun 2026

Review uses evolutionary lens to examine modern human aging rates

A review article now published in "Nature Reviews Genetics" brings together evolutionary theory, comparative genomics and large-scale human genetics to explain why we age and why aging rates differ among individuals and species.

11 Jun 2026

Active β-catenin promotes aggressive spread of childhood bone cancer

A new research paper was recently published in Volume 17 of Genes & Cancer, titled "Active Beta-Catenin (ABC) promotes an invasive phenotype in pediatric osteosarcoma."

9 Jun 2026

Anti-aging herbal extract shows promise against chronic renal failure

Announcing a new publication for Acta Materia Medica journal. Chronic renal failure (CRF) is a progressive disease characterized by a sustained loss of kidney function, for which current therapies remain insufficient.

5 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026